Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

223 results about "T-Cell Epitopes" patented technology

T-cell epitope mapping. T-cell epitopes are defined as peptide sequences which, in association with proteins on antigen-presenting cells (APC), are required for recognition by specific T-cells.

Brucella recombinant multivalent epitope vaccine

PendingCN119015404Aavoid decompositionprecise targetingBacterial antigen ingredientsAntibacterial agentsAnaphylaxisHuman brucellosis
The invention belongs to the technical field of biomedicine, and particularly discloses a Brucella recombinant multivalent epitope vaccine which comprises IgVCTLA-4, a connected CD8 < + > T cell epitope, a connected CD4 < + > T cell epitope, a connected linear B cell epitope and a connected conformation B cell epitope. The protein of the vaccine provided by the invention is stable, hydrophilic and soluble, does not have anaphylaxis, has good immunogenicity, is expected to activate an organism to generate an effective immune response against brucella infection, blocks infection between livestock and people, realizes effective prevention and control of human brucellosis, and has good application prospects. The method can be a powerful method for preventing the occurrence and development of brucellosis in the future.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY

Immunogenicity prediction method and device based on multimode fusion and storage medium

The invention provides an immunogenicity prediction method and device based on multimode fusion and a storage medium. The method comprises the following steps: constructing a multimode prediction model; obtaining each data set; correspondingly training a multi-modal prediction model based on each data set to obtain a trained multi-modal prediction model; fusing the trained multi-modal prediction models, and constructing an immunogenicity comprehensive evaluation model; forming an intelligent immunogenicity prediction system based on the trained multi-modal prediction model and the immunogenicity comprehensive evaluation model; and performing immunogenicity prediction on the to-be-predicted protein based on the immunogenicity prediction intelligent system to obtain a test result, the test result comprising the immunogenicity risk score of the to-be-predicted protein and the potential immunogenicity T cell epitope on the to-be-predicted protein. According to the method, the effect of directionally optimizing the immunogenicity on the basis of the prediction result can be achieved, and the drug effect and safety of protein biological drugs can be improved.
Owner:WECOMPUT TECHNOLOGY CO LTD

T cell epitope high-throughput screening method and device based on deep learning framework

The invention relates to the technical field of biological information prediction, and provides a T cell epitope high-throughput screening method and device based on a deep learning framework, and the method comprises the steps: extracting target input data according to an input T cell receptor sequence and an antigen sequence; wherein the target input data comprises a T cell receptor CDR3 beta sequence and at least one antigen epitope peptide fragment sequence; inputting the target input data into a pre-constructed prediction model to obtain a prediction result; and screening according to the prediction result to obtain a screening result. According to the method, a T cell receptor sequence and an antigen sequence which are not subjected to standardization treatment are allowed to be input, the CDR3 beta sequence can be efficiently extracted, then the binding activity prediction work is effectively carried out, the data preprocessing workload of an operator is reduced while the universality and the stability are improved, and the detection efficiency is improved. Meanwhile, the T cell receptor and epitope binding probability is predicted based on the deep neural network, and screening work is effectively completed.
Owner:SUZHOU CHUANGTENG SOFTWARE CO LTD

RNA cancer vaccines

The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal T cell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response.
Owner:MODERNATX INC

African swine fever virus T cell epitope peptide for inducing swine T cell immune response and application of African swine fever virus T cell epitope peptide

The invention discloses an African swine fever virus T cell epitope peptide for inducing swine T cell immune response and a composition of the African swine fever virus T cell epitope peptide. The amino acid sequence of the African swine fever virus T cell epitope peptide is shown as any one of SEQ ID NO.1-19. Or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1-19 and maintains the protein function shown in SEQ ID NO.1-19 through substitution and / or deletion and / or addition of one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1-19; the composition comprises amino acids of which the sequences are SEQ ID NO.1-19. A group of ASFV key T cell antigens and epitope peptides are obtained by combining IFN-gamma ELISpot and flow cytometry screening, the ASFV key T cell antigens and epitope peptides can be used as vaccine components to induce strong T cell immune response, and T cells activated by the antigen peptides have the maximum immune protection potential and are essential key antigens for ASFV vaccine research and development.
Owner:YANGZHOU UNIV +1

Compositions of nucleic acid nanostructures for vaccines and methods of use thereof

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.
Owner:MASSACHUSETTS INST OF TECH

Cow milk allergen epitopes, megapools and uses thereof

PCT designated stage expiredWO2025128638A1Antibody mimetics/scaffoldsPeptide/protein ingredientsMilk allergyProteinoid
The present invention includes compositions, including epitope megapools, and methods for detecting the presence of cow milk allergen(s), specifically T cell epitopes for T cells responsive to one or more cow milk peptides or proteins comprising, consisting of, or consisting essentially of: one or more peptides or proteins selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein comprising one or more amino acid sequences selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such protein(s) or peptide(s).
Owner:LA JOLLA INST FOR IMMUNOLOGY

SARS-COV-2 variants of concern-specific multi-antigens universal vaccine

Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and / or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and / or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).
Owner:RGT UNIV OF CALIFORNIA

Coronavirus T Cell Epitopes, Megapools and Uses Thereof

The present disclosure includes compositions and methods for detecting the presence of: a coronavirus or an immune response relevant to a coronavirus infection including T cells responsive to one or more coronavirus peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences selected from those sequences set forth in Tables 1 to 10 (SEQ ID NOS: 1 to 3522), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein; a pool of 2 or more peptides; or a polynucleotide that encodes one or more peptides or proteins, comprising, consisting of, or consisting essentially of one or more amino acid sequences set forth in Tables 1 to 10 (SEQ ID NOS: 1 to 3522), or a subsequence, portion, homologue, variant or derivative thereof. The disclosure further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.
Owner:LA JOLLA INST FOR IMMUNOLOGY

Predicting the immunogenicity of T cell epitopes

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether a modification in a peptide or polypeptide, such as a tumor-associated neoantigen, is immunogenic. The methods of the present invention are particularly suitable for providing a vaccine specific to a patient's tumor and, therefore, are suitable for use in the context of personalized cancer vaccines.
Owner:BIONTECH SE +1

HLA-ii immunopeptidome methods and systems for antigen discovery

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.
Owner:THE BROAD INST INC +1

T cell epitope peptide of Oratosquilla oratoria allergen tropomyosin and application of T cell epitope peptide

The invention provides a T cell epitope peptide of Oratosquilla oratoria allergen tropomyosin and application thereof, the T cell epitope peptide is any one or more of the following epitope polypeptides, and the amino acid sequences of the epitope polypeptides are shown as SEQ ID NO: 1-4. According to the invention, 10 T cell epitope peptides are predicted by using bioinformatics software. Four T cell epitope peptides without IgE reactivity are identified by combining a CD4 + T cell proliferation experiment with the release level of IL-2 and a serological experiment; the T-cell epitope tandem peptide with immune tolerance potential is designed based on the T-cell epitope peptide and can be developed into a desensitization preparation for preventing or treating shrimp allergy, and a new strategy is provided for developing a food allergy immunotherapy.
Owner:XIAMEN OCEAN VOCATIONAL & TECH COLLEGE

Multi-epitope peptide of novel coronavirus, vaccine as well as preparation method and application of multi-epitope peptide and vaccine

The invention discloses a multi-epitope peptide of novel coronavirus, a vaccine as well as a preparation method and application of the multi-epitope peptide, and belongs to the technical field of preparation of polypeptide vaccines. The multi-epitope peptide of the novel coronavirus not only contains T cell epitopes, but also contains B cell epitopes, and can induce humoral immunity and cellular immunity responses of an organism at the same time; the vaccine comprises epitopes from four antigenic proteins of novel coronavirus, and can induce comprehensive immune response. According to the multi-epitope peptide vaccine based on the novel coronavirus, the nano-carrier KFE8 serves as a delivery carrier, different antigen epitopes of the same pathogen or antigen epitopes of different pathogens can be presented in a mixed mode, safety is good, large-scale rapid preparation is achieved in an emergency state, and the vaccine is suitable for large-scale popularization and application. The coronavirus vaccine is a novel coronavirus universal vaccine which can cover various pathogen subtypes and induce broad-spectrum and long-term immune effects.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Nanoparticles comprising amphiphilic polymers and lipids for the targeted delivery of antigens

PCT designated stage expiredWO2025149619A1Peptide/protein ingredientsMicrocapsulesAntigenDisease
The present application relates to nanoparticles comprising (a) an amphiphilic polymer; (b) a first lipid comprising a polar head group and a non-polar tail group; and (c) a peptide comprising a T cell epitope. Also disclosed are populations of said nanoparticles, processes for manufacturing said nanoparticles, precursors for manufacturing said nanoparticles, pharmaceutical compositions of said nanoparticles, and methods of treating a disease or disorder comprising administering said nanoparticles to a subject.
Owner:TOPAS THERAPEUTICS GMBH

Coronavirus T Cell Epitopes and Uses Thereof

The present disclosure includes compositions and methods for detecting the presence of: a coronavirus or an immune response relevant to a coronavirus infection including T cells responsive to one or more coronavirus peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences selected from those sequences set forth in Table 2 (SEQ ID NOS: 1 to 292), Table 3 (SEQ ID NOS: 293 to 347), or both, or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein; a pool of 2 or more peptides; or a polynucleotide that encodes one or more peptides or proteins, comprising, consisting of, or consisting essentially of one or more amino acid sequences set forth in Table 2 or Table 3, or a subsequence, portion, homologue, variant or derivative thereof. The disclosure further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.
Owner:LA JOLLA INST FOR IMMUNOLOGY

CTLA-4 / B7-based targeted APC immune-enhanced echinococcosis multi-epitope vaccine

In order to seek an echinococcosis antigen which has good immunogenicity and can activate an organism to generate an effective immune response against echinococcosis granulosa infection, the invention provides an echinococcosis multi-epitope antigen and application thereof in preparation of a vaccine for preventing echinococcosis. The multi-epitope antigen is formed by sequentially connecting CTLA-4-lgV, a T cell epitope of EgA31, a T cell epitope of EgG1Y162, a B cell epitope of EgA31 and a B cell epitope of EgG1Y162 in series, the multi-epitope antigen can be specifically combined with serum of a cystic echinococcosis patient, a mouse immunized by a vaccine can generate specific B cell response and generate specific cellular immunity and an antibody, and the multi-epitope antigen has good immunogenicity.
Owner:XINJIANG MEDICAL UNIV

Recombinant fusion protein for antigen delivery and uses thereof

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.
Owner:LG CHEM LTD

Polypeptide for activating cellular immunity in chronic hepatitis B and application thereof

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.
Owner:广东凯博生物科技有限公司

Earlabacterium tulafaciens Tul4 protein tripolymer and application thereof in vaccine preparation

The invention provides a tulabacillus Tul4 protein trimer, according to the Tul4 protein trimer, an N-terminal natural Loop region of a monomer of the Tul4 protein trimer is used as flexible connection, Tul4 proteins are connected in series to form the trimer Tul4-trimer, the trimer can retain monomer conformation before fusion and fully expose important T cell epitopes of the monomer, an Ad5-Tul4-trimer vector based on type-5 adenovirus is constructed, and the tulabacillus Tul4 protein trimer can be used for preparing the Tul4 protein trimer. According to the present invention, the Tul4 trimer with the high expression can be obtained in the host cell, the Tul4 trimer can induce the efficient specific humoral immune response under the intramuscular injection and nasal drip immune pathway, the latter can induce the strong mucosal immune response, and the Tul4 trimer can be used for preparing the vaccine for preventing the Tul4 infection or the drug for treating the Tul4 infection.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Modified proteins

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising the modified proteins, their manufacture and the use of such compositions in medicine. More particularly, it relates to a modified Sap2 (Secreted Aspartyl Proteinase 2 of Candida albicans') protein. The modified Sap2 protein can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA

T cell epitopes associated with type 1 diabetes

Provided herein are T cell epitopes associated with Type 1 diabetes. Also provided are antigen-presenting cells presenting such epitopes. T cells reactive to such epitopes, and related compositions and therapies.
Owner:COGEN IMMUNE MEDICINE INC

Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector

The present disclosure relates to PD-L1-binding molecules comprising a Shiga toxin effector region, a PD-L1-binding region, and a T cell epitope, and pharmaceutical compositions thereof. The PD-L1 binding molecules and pharmaceutical compositions thereof have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and / or immune cells), for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutics for treating or slowing the progression of cancer (e.g., non-small cell lung cancer or squamous cell carcinoma of the head and neck). The present disclosure also relates to clinical methods for use of the disclosed PD-L1 binding molecules for treating a subject in need thereof.
Owner:MOLECULAR TEMPLATES INC

EBV tumor vaccine and application thereof

The invention belongs to the technical field of biological medicines, and discloses an EBV (Epstein-Barr Virus) tumor vaccine and application thereof. The invention discloses a novel EBV vaccine antigen combination for the first time. The novel EBV vaccine antigen combination comprises BZLF1, EBNA1, EBNA3B and gHgL. The applicant carries out antigen modification on BZLF1, EBNA1 and EBNA3B, and safety modification is completed while antigen T cell epitopes are retained. A humanized mouse proves that the antigen combination has good safety, immunity and protection effects, and EBV infected cells can be killed by activating BZLF1, EBNA1 and EBNA3B antigen specific T cells, so that EBV tumors are effectively prevented. The vaccine of the antigen combination can be used for preventing EBV related tumors, such as lymphoma, lymphatic proliferative diseases after transplantation, nasopharynx cancer and gastric cancer.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Tp0136T cell epitope mRNA vaccine based on lipid nanoparticle delivery and application of Tp0136T cell epitope mRNA vaccine in syphilis prevention

The invention relates to the technical field of mRNA vaccine research and development, and discloses a Tp0136T cell epitope mRNA vaccine based on lipid nanoparticle delivery and application of the Tp0136T cell epitope mRNA vaccine in syphilis prevention, the vaccine contains an mRNA sequence and an LNP delivery system, the mRNA sequence contains a Tp0136T1T cell epitope coding region (amino acid L477-S486, optimized by codon), a Cap 1 structure, optimized UTR and poly (A) tails of 65-76 adenosine, and psi or m5C is used for replacing trona; the LNP is prepared from SM-102, DSPC (Distearoyl Pyrrolidone), cholesterol and DMG-PEG (Dimethyl Glycol-Polyethylene Glycol) according to a molar ratio of 50 The particle size of the vaccine is less than or equal to 150nm, PDIlt; 0.2, the Zeta potential is-5 to-15 mV, and the encapsulation efficiency is greater than or equal to 93.47%. The preparation method comprises the steps of mRNA design synthesis, mRNA-LNP preparation characterization and in-vitro expression verification, through intramuscular injection inoculation, strong Th1 type and CD8 + CTL immune response can be induced, treponema pallidum load and skin ulcer rate can be reduced, and the method can be used for syphilis prevention.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES

Methods and compositions for cancer treatment using recombinant polypeptides

This disclosure provides a method for treating cancer in human subjects, comprising the administration of a recombinant polypeptide containing a cancer-specific CD8+ T cell epitope. The peptide, recognized by a major histocompatibility complex (MHC) molecule, can activate a T cell immune response to target cancer cells in the subject. This disclosure further provides a cancer-specific CD8+ T cell epitope constrained to an MHC molecule expressed by a specific HLA allele in the subject. This disclosure further provides a composition encoding a recombinant polypeptide capable of inducing an augmented memory CD8+ T cell response.
Owner:INFINITOPES LTD

A recombinant fcv antigen and its construction method and application

The application discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence of a non-structural protein NS7 of FCV and a coding sequence of a SpyTag peptide segment through a coding sequence of a linker, then cloning into a baculovirus transfer vector to obtain a recombinant plasmid, and finally integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. The application selects NS7 as a core immunogen, guides the immune system to produce a high cellular immune response, and thus makes up for the deficiency of an existing vaccine in clearing intracellular viruses; meanwhile, a specific T cell epitope is selected in the sequence of NS7 as an immunogen, which can avoid the immunological escape caused by the variation degree of antigens among different strains and virus antigen drift, and thus provides broader protection.
Owner:SUZHOU WOMEI BIOLOGY CO LTD

CD4 + T cell targeting cryptosporidium parvum epitope polypeptide and application thereof

PendingCN119798456AProtozoa antigen ingredientsAntiparasitic agentsCryptosporidium parvumTGE VACCINE
The invention relates to an epitope polypeptide of cryptosporidium parvum targeting CD4 + T cells and application of the epitope polypeptide. The amino acid sequence of the epitope polypeptide is shown as SEQ ID NO.1; the epitope polypeptide is a combined long epitope polypeptide of cryptosporidium parvum Gp40 / 15 protein, Gp900 protein and CSL protein; the epitope polypeptide can be applied to a vaccine for preventing or treating cryptosporidiosis parvum, and after a mouse is immunized by the vaccine, not only can CD8 + T cell immune response of the mouse be obviously stimulated, but also stronger CD4 + T cell response is induced to be generated, and the mouse can be induced to generate multifunctional T cells related to an immune protection effect; the levels of IFN-gamma, TNF-alpha and IL-2 generated by multifunctional T cells induced by a long polypeptide immune group have extremely significant differences (P is less than 0.01) compared with various negative controls, which indicates that the long polypeptide epitope vaccine has corresponding biological immunological activity and becomes a novel cryptosporidium parvum infection resistant T cell epitope vaccine or an immunodominance T cell epitope-based mRNA vaccine.
Owner:ZHOUKOU NORMAL UNIV